Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for SG293 (In Vivo CAR-T) in B-Cell Cancers. The expected timing is based on the latest available company guidance and may change.
11/06/25:- IND for SG293 in B-cell cancers expected as early as 2027. 03/03/26:- First-in-human data in blood cancers expected in 2026; initial trial start also planned this year. 04/27/26:- ASGCT 2026 oral presentation on May 12, 2026 highlights SG293 preclinical NHP data. 05/11/26:- Preparing to start SG293 NHL trial in 2026; first-in-human data still expected this year. 05/12/26:- ASGCT 2026 oral showed NHP SG293 activity; plan NHL clinic later 2026; FIH data 2026. 08/10/26:- SG293 NHL clinical data still expected in 2026 after ASGCT preclinical NHP activity.
Verification
Confirm timing and program details against the company announcement or filing.